Latest videos

All news posts

Enorama Pharma secures financing through loan agreements of 17 million SEK and refinances existing loans of 18 million SEK with Swede Unipharma AB

The Board of Directors of Enorama Pharma AB (publ) ("Enorama Pharma" or "the Company") announces that the Company has entered into a loan agreement with the Company's principal owner Swede Unipharma AB and increases the Company's loan to a total of approximately 35 million SEK....

Enorama Pharma receives its second order for tobacco-free nicotine pouches

Enorama Pharma announces that the Company has received an order for tobacco-free nicotine pouches from the American company Turning Point Brands, Louisville, USA. The order is worth approximately SEK 1.9 million and the first products are expected to be delivered during the first...

Enorama Pharma receives order for tobacco-free nicotine pouches

Enorama Pharma announces that the Company has received an order for tobacco-free nicotine pouches from the American company Good Work Tech, New York, USA. The order is worth approximately SEK 1.1 million and the first products are expected to be delivered during the first half of...

Enorama Pharma submits applications for mutual recognition in 7 European countries

On September 18, 2019, Enorama Pharma announced to the Swedish Medical Products Agency which countries will be included in the Company's first MRP application for approval of the nicotine chewing gum in several markets within the EU. Enorama Pharma chooses to submit applications...

The Swedish MPA accepts Enorama Pharmas request for using Sweden as Reference Member State

Enorama Pharma announces that the request submitted to the Swedish Medical Products Agency on August 19, 2019 has been accepted and that Sweden thus will act as Reference Member State in the upcoming Mutual Recognition Procedure (MRP) application.

Read the full press release in...

Enorama Pharma receives approval for the nicotine chewing gum from the Swedish MPA

Enorama Pharma announces that the Company has received approval from the Swedish Medical Products Agency for each of the Company's four nicotine products - 2 mg and 4 mg chewing gum, respectively, with mint and fruit mint flavor. The application is Enorama's first medical product...

nicotine chewing gum

Enorama has submitted the proposed supplements on the MAA to the Swedish MPA

Enorama Pharma announces that proposed supplements to the Marketing Authorization Application (MAA) for each of the Company's four nicotine products - 2 mg and 4 mg chewing gum with mint and fruit mint flavor respectively - have been submitted July 18 2019, three days before...

Enorama Pharma's pathway towards a medical cannabis chewing gum

The potential market for medical cannabis is huge. Enorama Pharma's management believes that there will be a great need for serious cannabis products in the future. Enorama is currently working on prototype development of a cannabis chewing gum containing CBD that is primarily...